The effect of concomitant use of Colony-Stimulating factors on bleomycin pulmonary toxicity – A systematic review and meta-analysis

This publication has 59 references indexed in Scilit:

• Hodgkin lymphoma
  Critical Reviews in Oncology/Hematology, 2013
• Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman
  Journal of Oncology Pharmacy Practice, 2012
• Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study
  Leukemia & Lymphoma, 2011
• Mobilization of Bone Marrow Cells by CSF3 Protects Mice from Bleomycin-Induced Lung Injury
  Respiration, 2011
• Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
  European Journal of Epidemiology, 2010
• Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
  European Journal of Cancer, 2006
• Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2006
• Quantifying heterogeneity in a meta‐analysis
  Statistics in Medicine, 2002
• Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin
  European Journal of Cancer, 1996
• Cytotoxic drug-induced pneumonia and possible augmentation by G-CSF — clinical attention
  Annals of Hematology, 1993